Our Partnering Model
We have a history of successful partnerships with companies across markets
Our partnering model builds on
- an integrated business development and licensing (BD&L) approach, from target identification to project implementation
- broad market screening and scouting for new opportunities through dedicated teams
- state of the art deal-making, applying classical as well as innovative deal structuring
- professional deal implementation and cooperation through a dedicated Strategic Alliance Management function
As a worldwide leader in pain, we are currently strengthening our pain portfolio.
In parallel, we are expanding into pain-related indications as well as small or orphan indications.
In addition, we are exploring medical devices and technology platforms – for markets in Europe, Latin America and the U.S.
In 2016, we entered the hospital market in Europe with Zalviso®, a pre-programmed, non-invasive device for the management of acute post-operative pain, and we are looking for further opportunities in the hospital market.
Read our recent press releases on Grünenthal partnering projects
-
Grünenthal to acquire commercialization rights of Qutenza® in Europe from Astellas Pharma Europe
-
Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
-
Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America
-
Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America
-
Grünenthal Group to Acquire Almirall de Mexico, S.A. de C.V.
-
Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD)
-
Grünenthal GmbH exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership
-
Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients
-
Grünenthal GmbH granted its consent to the transfer of the license rights for Nucynta® (tapentadol) in the U.S. from Janssen Pharmaceuticals, Inc., to Depomed, Inc.
-
Grünenthal Announces Termination of License Agreement with Actavis for the Development of Cebranopadol as of October 1, 2014
-
Grünenthal significantly strengthens its pain product portfolio in Europe
-
Grünenthal completes acquisition of Empresas Andrómaco
-
Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
-
Grünenthal launches public tender offer to the shareholders of Empresas Andrómaco
-
Grünenthal takes over a product portfolio of BIOGEN® LABORATORIOS
-
The Grünenthal Group Enters into Exclusive Agreement with Horizon Pharma for Commercialization of DUEXIS® in Latin America
